Emergent BioSolutions (EBS) Income from Non-Controlling Interests (2011 - 2013)
Emergent BioSolutions (EBS) posted quarterly Income from Non-Controlling Interests of -$5000.0 for Q4 2013, up 99.55% year-over-year from -$2505.7 in Q4 2012, and up 96.09% quarter-over-quarter from -$128000.0 in Q2 2013.
Emergent BioSolutions (EBS) Income from Non-Controlling Interests (2011 - 2013) Analysis & Trends
Emergent BioSolutions' Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at -$5000.0 for Q4 2013.
- In Q4 2013, Income from Non-Controlling Interests rose 99.55% year-over-year to -$5000.0; the TTM figure through Sep 2014 stood at -$5000.0 (up 99.75% YoY), while the FY2013 annual figure was -$876000.0, up 83.72% from the prior year.
- Income from Non-Controlling Interests for Q4 2013 stood at -$5000.0, up from -$128000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was -$5000.0 in Q4 2013, with the low at -$2.1 million in Q2 2012.
- The 3-year median for Income from Non-Controlling Interests is -$1.1 million (2012), against an average of -$1.1 million.
- The sharpest annual moves came in 2012 and 2013: Income from Non-Controlling Interests fell 23.65% in 2012, then jumped 99.55% in 2013.
- Emergent BioSolutions' Income from Non-Controlling Interests stood at -$1.8 million in 2011, then surged by 37.11% to -$1.1 million in 2012, then surged by 99.55% to -$5000.0 in 2013.
- Business Quant data shows EBS's Income from Non-Controlling Interests at -$5000.0 in Q4 2013, -$128000.0 in Q2 2013, and -$743000.0 in Q1 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Emergent BioSolutions | 251.03 Mn | 110.13 Mn | 137.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | -5,000.00 |
| Jun 30, 2013 | -128,000.00 |
| Mar 31, 2013 | -743,000.00 |
| Dec 31, 2012 | -1.11 Mn |
| Sep 30, 2012 | -997,000.00 |
| Jun 30, 2012 | -2.09 Mn |
| Mar 31, 2012 | -1.19 Mn |
| Dec 31, 2011 | -1.76 Mn |
| Sep 30, 2011 | -1.69 Mn |
| Jun 30, 2011 | -1.69 Mn |